JP7166659B2 - 急性腎障害の検査方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬 - Google Patents

急性腎障害の検査方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬 Download PDF

Info

Publication number
JP7166659B2
JP7166659B2 JP2020551095A JP2020551095A JP7166659B2 JP 7166659 B2 JP7166659 B2 JP 7166659B2 JP 2020551095 A JP2020551095 A JP 2020551095A JP 2020551095 A JP2020551095 A JP 2020551095A JP 7166659 B2 JP7166659 B2 JP 7166659B2
Authority
JP
Japan
Prior art keywords
mirna
kidney injury
acute kidney
acute
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020551095A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020071518A1 (ja
Inventor
義幸 森下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jichi Medical University
Original Assignee
Jichi Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jichi Medical University filed Critical Jichi Medical University
Publication of JPWO2020071518A1 publication Critical patent/JPWO2020071518A1/ja
Application granted granted Critical
Publication of JP7166659B2 publication Critical patent/JP7166659B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020551095A 2018-10-04 2019-10-04 急性腎障害の検査方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬 Active JP7166659B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018188746 2018-10-04
JP2018188746 2018-10-04
PCT/JP2019/039227 WO2020071518A1 (ja) 2018-10-04 2019-10-04 急性腎障害特異的バイオマーカー、急性腎障害の診断方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬

Publications (2)

Publication Number Publication Date
JPWO2020071518A1 JPWO2020071518A1 (ja) 2021-12-02
JP7166659B2 true JP7166659B2 (ja) 2022-11-08

Family

ID=70055469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551095A Active JP7166659B2 (ja) 2018-10-04 2019-10-04 急性腎障害の検査方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬

Country Status (5)

Country Link
US (1) US20220002803A1 (zh)
EP (1) EP3862438A4 (zh)
JP (1) JP7166659B2 (zh)
CN (1) CN112789356A (zh)
WO (1) WO2020071518A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503617A (ja) 2009-09-04 2013-02-04 フンダシオン・パラ・ラ・インベスティガシオン・ビオメディカ・デル・オスピタル・ウニベルシタリオ・ラモン・イ・カハル 急性腎損傷の診断および／または予後方法
JP2015501650A (ja) 2011-12-15 2015-01-19 フンダシオン・パラ・ラ・インベスティガシオン・ビオメディカ・デル・オスピタル・ウニベルシタリオ・ラモン・イ・カハルＦｕｎｄａｃｉｏｎｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｃｉｏｎ Ｂｉｏｍｅｄｉｃａ Ｄｅｌ Ｈｏｓｐｉｔａｌ Ｕｎｉｖｅｒｓｉｔａｒｉｏ Ｒａｍｏｎ Ｙ Ｃａｊａｌ 急性腎障害の診断および／または予後診断方法
WO2015190591A1 (ja) 2014-06-13 2015-12-17 東レ株式会社 乳がんの検出キット又はデバイス及び検出方法
WO2015194615A1 (ja) 2014-06-18 2015-12-23 東レ株式会社 肝臓がんの検出キット又はデバイス及び検出方法
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
WO2017171048A1 (ja) 2016-03-31 2017-10-05 東レ株式会社 早期膵がん又は膵がん前駆病変の検出キット又はデバイス及び検出方法
JP2018506998A (ja) 2015-03-02 2018-03-15 アクソーラボズ ゲーエムベーハー オリゴヌクレオチドの同時検出法、それに関するキットおよび使用法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907802A2 (pt) * 2008-02-29 2016-08-23 Univ Nagoya Nat Univ Corp biomarcador para lesão renal aguda e estimativa de seu prognóstico, e sua aplicação
JP2013514277A (ja) 2009-12-16 2013-04-25 ザ ユニバーシティ オブ ウェスタン オンタリオ 糖尿病におけるｍｉＲＮＡに関連する組成物と方法
CN104569417B (zh) * 2013-10-12 2016-06-01 广州瑞博奥生物科技有限公司 一种用于早期诊断急性肾损伤的抗体芯片试剂盒

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503617A (ja) 2009-09-04 2013-02-04 フンダシオン・パラ・ラ・インベスティガシオン・ビオメディカ・デル・オスピタル・ウニベルシタリオ・ラモン・イ・カハル 急性腎損傷の診断および／または予後方法
JP2015501650A (ja) 2011-12-15 2015-01-19 フンダシオン・パラ・ラ・インベスティガシオン・ビオメディカ・デル・オスピタル・ウニベルシタリオ・ラモン・イ・カハルＦｕｎｄａｃｉｏｎｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｃｉｏｎ Ｂｉｏｍｅｄｉｃａ Ｄｅｌ Ｈｏｓｐｉｔａｌ Ｕｎｉｖｅｒｓｉｔａｒｉｏ Ｒａｍｏｎ Ｙ Ｃａｊａｌ 急性腎障害の診断および／または予後診断方法
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
WO2015190591A1 (ja) 2014-06-13 2015-12-17 東レ株式会社 乳がんの検出キット又はデバイス及び検出方法
WO2015194615A1 (ja) 2014-06-18 2015-12-23 東レ株式会社 肝臓がんの検出キット又はデバイス及び検出方法
JP2018506998A (ja) 2015-03-02 2018-03-15 アクソーラボズ ゲーエムベーハー オリゴヌクレオチドの同時検出法、それに関するキットおよび使用法
WO2017171048A1 (ja) 2016-03-31 2017-10-05 東レ株式会社 早期膵がん又は膵がん前駆病変の検出キット又はデバイス及び検出方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIJIIWA, Yoshiro et al.，Overexpression of microRNA-5100 decreases the aggressive phenotype of pancreatic cancer cells by tar，INTERNATIONAL JOURNAL OF ONCOLOGY，2016年，vol. 48，p. 1688-1700
WANG, Jia-feng et al.，Screening plasma miRNAs as biomarkers for renal ischemia-reperfusion injury in rats，Med. Sci. Monit.，2014年，vol. 20，p. 283-289
WANG, Nan et al.，Urinary MicroRNA-10a and MicroRNA-30d Serve as Novel, Sensitive and Specific Biomarkers for Kidney I，PLOS ONE，2012年，vol. 7, iss. 12，e51140

Also Published As

Publication number Publication date
US20220002803A1 (en) 2022-01-06
CN112789356A (zh) 2021-05-11
JPWO2020071518A1 (ja) 2021-12-02
EP3862438A1 (en) 2021-08-11
EP3862438A4 (en) 2022-08-03
WO2020071518A1 (ja) 2020-04-09

Similar Documents

Publication Publication Date Title
Berria et al. Increased collagen content in insulin-resistant skeletal muscle
Chen et al. Nrf2 deficiency aggravates Angiotensin II-induced cardiac injury by increasing hypertrophy and enhancing IL-6/STAT3-dependent inflammation
AU2013266086B2 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
US20170058349A1 (en) Methods for managing care of patients predisposed to progressive mitral valve diseases
JP5299900B2 (ja) 糖尿病関連肝臓由来分泌タンパク質の２型糖尿病または血管障害の診断または治療への利用
JP6465923B2 (ja) 膵臓β細胞障害における可溶性ＭＡＮＦ
Li et al. Sclt1 deficiency causes cystic kidney by activating ERK and STAT3 signaling
KR102242639B1 (ko) 간 섬유화 진단용 바이오마커 miRNA4668-5p
Shi et al. Zebrafish hhatla is involved in cardiac hypertrophy
Kocyigit et al. Systemic succinate, hypoxia-inducible Factor-1 alpha, and IL-1β gene expression in autosomal dominant polycystic kidney disease with and without hypertension
JP7166659B2 (ja) 急性腎障害の検査方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬
CN108004310A (zh) 肾素(原)受体(p)rr基因及其抑制剂的应用
JP7120663B2 (ja) 糖尿病性腎臓病の診断することを補助する方法、糖尿病性腎臓病の検査用キット、動物治療方法、及び糖尿病性腎臓病用医薬
TW201030340A (en) Method for renal disease diagnosis and prognosis using annexin a1 and rab23 as markers
US20140363380A1 (en) Mex3c regulation and target to control obesity and diabetes
CN111474364B (zh) 人rab22a的用途及相关产品
WO2019137138A1 (zh) 人gpnmb蛋白或其拮抗剂或激动剂的用途
CN112877437B (zh) 一种lncRNA在诊断和治疗口腔鳞癌中的应用
JP2014039484A (ja) 検体を提供する哺乳動物における神経病変の存在を検出するために有効なマイクロｒｎａ
WO2005012570A1 (ja) Slc25a10による肥満治療に有効な化合物の評価方法
Nxele Identification of sub-clinical biomarkers that predict the risk of developing diabetic cardiomyopathy
Zhang et al. Expression and function of miR-92a in ventricular remodeling after PCI treatment of acute myocardial in-farction
Forsythe Understanding the phenotype and preparing for therapeutics in Bardet-Biedl syndrome
CN111690729A (zh) 一种测定外周血npvf蛋白诊断湿性年龄相关性黄斑变性的方法
JPWO2014088118A1 (ja) 心病変マーカー及びその利用

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20210401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221019

R150 Certificate of patent or registration of utility model

Ref document number: 7166659

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150